Advertisement

Psychopharmacology

, Volume 236, Issue 2, pp 831–838 | Cite as

Elevated IL-16 expression is associated with development of immune dysfunction in children with autism

  • Sheikh F. AhmadEmail author
  • Mushtaq A. Ansari
  • Ahmed Nadeem
  • Saleh A. Bakheet
  • Laila Y. AL-Ayadhi
  • Sabry M. Attia
Original Investigation

Abstract

Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by impairments in communication skills and social behaviors. Several studies have suggested that neuroimmune dysfunction plays a significant role in the pathogenesis of ASD; however, its exact etiology is unknown. Interleukin-16 (IL-16), a chemoattractant, is associated with various inflammatory processes. However, its role in children with ASD is unclear. This study aimed to investigate whether IL-16 expression is associated with immune dysfunction in children with ASD. We examined IL-16 expression in CD4+, CD8+, CD14+, CCR3+, and CXCR7+ cells in typically developing (TD) controls and children with ASD using flow cytometry in peripheral blood mononuclear cells (PBMCs). We also investigated the expression of IL-1β+IL-16+, IL-6+IL-16+, and TNF-α+IL-16+ in TD controls and children with ASD. We further explored IL-16 mRNA and protein expression using RT-PCR and western blotting. CD4+IL-16+, CD8+IL-16+, CD14+IL-16+, CCR3+IL-16+, and CXCR7+IL-16+ cells increased significantly in children with ASD compared with TD controls. We also showed that expression of IL-1β+IL-16+, IL-6+IL-16+, and TNF-α+IL-16+ was elevated in children with ASD compared with TD controls. Moreover, IL-16 mRNA and protein expression was significantly induced in children with ASD compared with TD controls. These results suggest that IL-16 expression could play an essential role in immune alteration in children with ASD.

Keywords

Typically developing controls Autism spectrum disorder Peripheral blood mononuclear cells Interleukin-16 Cytokines 

Notes

Funding information

The Deanship of Scientific Research at King Saud University funded this work through the research group project No. RGP-120.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. Ahearne CE, Chang RY, Walsh BH, Boylan GB, Murray DM (2017) Cord blood IL-16 is associated with 3-year neurodevelopmental outcomes in perinatal asphyxia and hypoxic-Ischaemic encephalopathy. Dev Neurosci 39(1–4):59–65CrossRefGoogle Scholar
  2. Ahmad SF, Nadeem A, Ansari MA, Bakheet SA, Attia SM, Zoheir KMA, al-Ayadhi LY, Alzahrani MZ, Alsaad AMS, Alotaibi MR, Abd-Allah ARA (2017a) Imbalance between the anti- and pro-inflammatory milieu in blood leukocytes of autistic children. Mol Immunol 82:57–65CrossRefGoogle Scholar
  3. Ahmad SF, Zoheir KMA, Ansari MA, Nadeem A, Bakheet SA, al-Ayadhi LY, Alzahrani MZ, al-Shabanah OA, al-Harbi MM, Attia SM (2017b) Dysregulation of Th1, Th2, Th17, and T regulatory cell-related transcription factor signaling in children with autism. Mol Neurobiol 54(6):4390–4400CrossRefGoogle Scholar
  4. Ahmad SF, Nadeem A, Ansari MA, Bakheet SA et al (2017c) Upregulation of IL-9 and JAK-STAT signaling pathway in children with autism. Prog Neuropsychopharmacol Biol Psychiatry 79(Pt B):472–480CrossRefGoogle Scholar
  5. Ahmad SF, Ansari MA, Nadeem A, Bakheet SA, al-Ayadhi LY, Attia SM (2018) Upregulation of peripheral CXC and CC chemokine receptor expression on CD4+ T cells is associated with immune dysregulation in children with autism. Prog Neuro-Psychopharmacol Biol Psychiatry 81:211–220CrossRefGoogle Scholar
  6. American Psychiatric Association (2015) Diagnostic and statistical manual of mental disorders, 5th edn. American Psychiatric Association, Washington, DCGoogle Scholar
  7. Ashwood P, Wakefield AJ (2006) Immune activation of peripheral blood and mucosal CD3+ lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms. J Neuroimmunol 173(1–2):126–134CrossRefGoogle Scholar
  8. Ashwood P, Enstrom A, Krakowiak P, Hertz-Picciotto I et al (2008) Decreased transforming growth factor β1 in autism: a potential link between immune dysregulation and impairment in clinical behavioral outcomes. J Neuroimmunol 204(1–2):149–153CrossRefGoogle Scholar
  9. Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah IN, van de Water J (2011a) Altered T cell responses in children with autism. Brain Behav Immun 25:840–849CrossRefGoogle Scholar
  10. Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah I, van de Water J (2011b) Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome. Brain Behav Immun 25:40–45CrossRefGoogle Scholar
  11. Bajetto A, Bonavia R, Barbero S, Florio T, Schettini G (2001) Chemokines and their receptors in the central nervous system. Front Neuroendocrinol 22:147–184CrossRefGoogle Scholar
  12. Berman JS, Cruikshank WW, Center DM, Theodore AC, Beer DJ (1985) Chemoattractant lymphokines specific for the helper/inducer T-lymphocyte subset. Cell Immunol 95:105–112CrossRefGoogle Scholar
  13. Bilbo SD, Schwarz JM (2012) The immune system and developmental programming of brain and behavior. Front Neuroendocrinol 33(3):267–286CrossRefGoogle Scholar
  14. Cabanlit M, Wills S, Goines P, Ashwood P, Van de Water J (2007) Brain-specific autoantibodies in the plasma of subjects with autistic spectrum disorder. Ann N Y Acad Sci 1107:92–103CrossRefGoogle Scholar
  15. Careaga M, Rogers S, Hansen RL, Amaral DG, Van de Water J, Ashwood P (2017) Immune endophenotypes in children with autism spectrum disorder. Biol Psychiatry 81(5):434–441CrossRefGoogle Scholar
  16. Chen YC, Tsai WJ, Wu MH, Lin LC, Kuo YC (2007) Suberosin inhibits proliferation of human peripheral blood mononuclear cells through the modulation of the transcription factors NF-AT and NF-kappaB. Br J Pharmacol 150(3):298–312CrossRefGoogle Scholar
  17. Choi JE, Widjaja F, Careaga M, Bent S, Ashwood P, Hendren RL (2014) Change in plasma cytokine levels during risperidone treatment in children with autism. J Child Adolesc Psychopharmacol 24(10):586–589CrossRefGoogle Scholar
  18. Croq F, Vizioli J, Tuzova M, Tahtouh M, Sautiere PE, van Camp C, Salzet M, Cruikshank WW, Pestel J, Lefebvre C (2010) A homologous form of human interleukin 16 is implicated in microglia recruitment following nervous system injury in leech Hirudo medicinalis. Glia 58:1649–1662CrossRefGoogle Scholar
  19. Cruikshank W, Little F (2008) Interleukin-16: the ins and outs of regulating T-cell activation. Crit Rev Immunol 28(6):467–483CrossRefGoogle Scholar
  20. Cruikshank WW, Kornfeld H, Center DM (2000) Interleukin-16. J Leukoc Biol 67:757–766CrossRefGoogle Scholar
  21. Deverman BE, Patterson PH (2009) Cytokines and CNS development. Neuron 64(1):61–78CrossRefGoogle Scholar
  22. Djukic M, Mildner A, Schmidt H et al (2006) Circulating monocytes engraft in the brain, differentiate into microglia and contribute to the pathology following meningitis in mice. Brain 129(Pt 9):2394–2403CrossRefGoogle Scholar
  23. Eftekharian MM, Ghafouri-Fard S, Noroozi R, Omrani MD, Arsang-jang S, Ganji M, Gharzi V, Noroozi H, Komaki A, Mazdeh M, Taheri M (2018) Cytokine profile in autistic patients. Cytokine 108:120–126CrossRefGoogle Scholar
  24. Estes ML, McAllister AK (2015) Immune mediators in the brain and peripheral tissues in autism spectrum disorder. Nat Rev Neurosci 16:469–486CrossRefGoogle Scholar
  25. Glass WG, Sarisky RT, Vecchio AM (2006) Not-so-sweet sixteen: the role of IL-16 in infectious and immune-mediated inflammatory diseases. J Interf Cytokine Res 26:511–520CrossRefGoogle Scholar
  26. Hsiao EY (2013) Immune dysregulation in autism spectrum disorder. Int Rev Neurobiol 113:269–302CrossRefGoogle Scholar
  27. Jones KL, Croen LA, Yoshida CK, Heuer L, Hansen R, Zerbo O, DeLorenze GN, Kharrazi M, Yolken R, Ashwood P, van de Water J (2017) Autism with intellectual disability is associated with increased levels of maternal cytokines and chemokines during gestation. Mol Psychiatry 22:273–279CrossRefGoogle Scholar
  28. Jyonouchi H, Geng L, Streck DL, Toruner GA (2011) Children with autism spectrum disorders (ASD) who exhibit chronic gastrointestinal (GI) symptoms and marked fluctuation of behavioral symptoms exhibit distinct innate immune abnormalities and transcriptional profiles of peripheral blood (PB) monocytes. J Neuroimmunol 238(1–2):73–80CrossRefGoogle Scholar
  29. Jyonouchi H, Geng L, Davidow AL (2014) Cytokine profiles by peripheral blood monocytes are associated with changes in behavioral symptoms following immune insults in a subset of ASD subjects: an inflammatory subtype? J Neuroinflammation 11:187CrossRefGoogle Scholar
  30. Klimiuk PA, Goronzy JJ, Weyand CM (1999) IL-16 as an anti-inflammatory cytokine in rheumatoid synovitis. J Immunol 162:4293–4299Google Scholar
  31. Li X, Chauhan A, Sheikh AM, Patil S, Chauhan V, Li XM, Ji L, Brown T, Malik M (2009) Elevated immune response in the brain of autistic patients. J Neuroimmunol 207(1–2):111–116CrossRefGoogle Scholar
  32. Li Y, Tang G, Liu Y, He X, Huang J, Lin X, Zhang Z, Yang GY, Wang Y (2015) CXCL12 gene therapy ameliorates ischemia-induced white matter injury in mouse brain. Stem Cells Transl Med 4(10):1122–1130CrossRefGoogle Scholar
  33. Luo QS, Wang JL, Deng YY, Huang HD, Fu HD, Li CY, Huang HN (2014) Interleukin-16 polymorphism is associated with an increased risk of glioma. Genet Test Mol Biomarkers 18:711–714CrossRefGoogle Scholar
  34. Mathy NL, Scheuer W, Lanzendorfer M, Honold K, Ambrosius D, Norley S, Kurth R (2000) Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes. Immunology 100:63–69CrossRefGoogle Scholar
  35. Mélik-Parsadaniantz S, Rostène W (2008) Chemokines and neuromodulation. J Neuroimmunol 198(1–2):62–68CrossRefGoogle Scholar
  36. Meltzer A, Van de Water J (2017) The role of the immune system in autism spectrum disorder. Neuropsychopharmacology 42:284–298CrossRefGoogle Scholar
  37. Mueller CA, Schluesener HJ, Conrad S, Pietsch T, Schwab JM (2006) Spinal cord injury-induced expression of the immune-regulatory chemokine interleukin-16 caused by activated microglia/macrophages and CD8+ cells. J Neurosurg Spine 4:233–240CrossRefGoogle Scholar
  38. Nadeem A, Ahmad SF, Attia SM, Bakheet SA, Al-Harbi NO, Al-Ayadhi LY (2018) Activation of IL-17 receptor leads to increased oxidative inflammation in peripheral monocytes of autistic children. Brain Behav Immun 67:335–344CrossRefGoogle Scholar
  39. Nadeem A, Ahmad SF, Attia SM, Al-Ayadhi LY, Al-Harbi NO, Bakheet SA (2019) Dysregulated enzymatic antioxidant network in peripheral neutrophils and monocytes in children with autism. Prog Neuro-Psychopharmacol Biol Psychiatry 88:352–359CrossRefGoogle Scholar
  40. Noriega DB, Savelkoul HFJ (2014) Immune dysregulation in autism spectrum disorder. Eur J Pediatr 173:33–43CrossRefGoogle Scholar
  41. Noster R, Riedel R, Mashreghi MF, Radbruch H et al (2014) IL-17 and GM-CSF expression are antagonistically regulated by human T helper cells. Sci Transl Med 6(241):241ra80CrossRefGoogle Scholar
  42. Onore C, Careaga M, Ashwood P (2012) The role of immune dysfunction in the pathophysiology of autism. Brain Behav Immun 26(3):383–392CrossRefGoogle Scholar
  43. Panaro MA, Lofrumento DD, Saponaro C, De Nuccio F, Cianciulli A, Mitolo V, Nicolardi G (2008) Expression of TLR4 and CD14 in the central nervous system (CNS) in a MPTP mouse model of Parkinson’s-like disease. Immunopharmacol Immunotoxicol 30(4):729–740CrossRefGoogle Scholar
  44. Rodriguez M, Alvarez-Erviti L, Blesa FJ, Rodríguez-Oroz MC, Arina A, Melero I, Ramos LI, Obeso JA (2007) Bone-marrow-derived cell differentiation into microglia: a study in a progressive mouse model of Parkinson's disease. Neurobiol Dis 28:316–325CrossRefGoogle Scholar
  45. Schonemeier B, Kolodziej A, Schulz S et al (2008) Regional and cellular localization of the CXCl12/SDF-1 chemokine receptor CXCR7 in the developing and adult rat brain. J Comp Neurol 510:207–220CrossRefGoogle Scholar
  46. Schopler E, Reichler RJ, Renner BR (1986) The Childhood Autism Rating Scale (CARS) for diagnostic screening and classification in autism. Irvington, New YorkGoogle Scholar
  47. Schwab JM, Schluesener HJ, Seid K, Meyermann R (2001) IL-16 is differentially expressed in the developing human fetal brain by microglial cells in zones of neuropoesis. Int J Dev Neurosci 19:93–100CrossRefGoogle Scholar
  48. Skundric DS, Dai R, Zakarian VL, Bessert D, Skoff RP, Cruikshank WW, Kurjakovic Z (2005) Anti-IL-16 therapy reduces CD4+ T-cell infiltration and improves paralysis and histopathology of relapsing EAE. J Neurosci Res 79(5):680–693CrossRefGoogle Scholar
  49. Skundric DS, Cruikshank WW, Drulovic J (2015) Role of IL-16 in CD4+ T cell-mediated regulation of relapsing multiple sclerosis. J Neuroinflamm 12:78CrossRefGoogle Scholar
  50. Vargas DL, Nascimbene C, Knshnan C, Zimmerman AW, Pardo CA (2005) Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol 57:67–81CrossRefGoogle Scholar
  51. Xu N, Li X, Zhong Y (2015) Inflammatory cytokines: potential biomarkers of immunologic dysfunction in autism spectrum disorders. Mediat Inflamm 2015:531518Google Scholar
  52. Zhang Z, Fauser U, Schluesener HJ (2008) Early attenuation of lesional interleukin-16 up-regulation by dexamethasone and FTY720 in experimental traumatic brain injury. Neuropathol Appl Neurobiol 34(3):330–339CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Pharmacology and Toxicology, College of PharmacyKing Saud UniversityRiyadhKingdom of Saudi Arabia
  2. 2.College of PharmacyKing Saud UniversityRiyadhSaudi Arabia
  3. 3.Autism Research and Treatment Center, AL-Amodi Autism Research Chair, Department of Physiology, College of MedicineKing Saud UniversityRiyadhKingdom of Saudi Arabia
  4. 4.Department of Pharmacology and Toxicology, College of PharmacyAl-Azhar UniversityCairoEgypt

Personalised recommendations